These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6992909)

  • 1. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
    Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
    Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
    Waters KJ; Craxford AD; Chamberlain J
    Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of naftidrofuryl in patients with intermittent claudication.
    Karnik R; Valentin A; Stöllberger C; Slany J
    Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
    Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
    Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
    [No Abstract]   [Full Text] [Related]  

  • 5. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
    Valentin A; Karnik R; Stöllberger C; Slany J
    Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
    Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
    Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
    Kriessmann A; Neiss A
    Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
    [No Abstract]   [Full Text] [Related]  

  • 8. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
    Goldsmith DR; Wellington K
    Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftidrofuryl for ischaemic rest pain: a controlled trial.
    Greenhalgh RM
    Br J Surg; 1981 Apr; 68(4):265-6. PubMed ID: 7013892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.
    Trübestein G; Böhme H; Heidrich H; Heinrich F; Hirche H; Maass U; Mörl H; Rudofsky G
    Angiology; 1984 Nov; 35(11):701-8. PubMed ID: 6388425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E; Bahnini A; Mouren X; Gamand S
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous naftidrofuryl on transcutaneous oxygen pressure in severe peripheral vascular disease.
    Taggart I; Wishart GC; Cuschieri RJ; MacBain GC
    Angiology; 1989 Oct; 40(10):895-8. PubMed ID: 2802260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
    Boccalon H; Lehert P; Mosnier M
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):175-82. PubMed ID: 12555510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.
    De Backer T; Vander Stichele R; Lehert P; Van Bortel L
    BMJ; 2009 Mar; 338():b603. PubMed ID: 19276131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D; Lehert P; Clement DL
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
    Diehm C; Kühn A; Strauss R; Hübsch-Müller C; Kübler W
    Vasa Suppl; 1989; 28():26-30. PubMed ID: 2609241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
    Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.